Yahoo Finance

Now time for some of today's trending tickers. You can scan the QR code below to track the best and the worst performing stocks of this session. All done on Yahoo Finance's trending tickers page. First up, let's take a look at Abbott. Abbott Labs missing fourth quarter sales expectations dragged down by weakness in its nutrition and diagnostics units. The medical device maker also forecasting first quarter profit below the street's expectations. Still though, the company's full-year outlook coming in in line with estimates. A bit of a silver lining there, I guess. Shares looking at gains of just about six-tenths of a percent. But when you drill down into these numbers here, there's some to be concerned about. When you take a look at diagnostic sales, that declined on a year-over-year basis, coming in just below what the street was looking for. Pharmaceutical sales was up slightly on a year-over-year basis, although again, just below what the street was looking for. And then medical devices that that's the one that stood stuck out to me there. Bit of a bright spot there. They did see some improvement on a year-over-year basis, but again, not enough to really move the needle. At least it looks like here with that small gain that we're seeing so far this in this morning's trading.

It's interesting the double-digit gains in medical device sales in the context of their COVID testing. Diagnostics unit down by double digits as well, over 30%. It speaks to this idea of these companies having to continue to reinvent themselves following the pandemic. Perhaps that's a little bit of what we're seeing here with Abbott. But TD Cohen noting that any pressure on the stock that we saw after that slight miss this morning could potentially be short-lived. And Bloomberg intelligence talking about how that there could be more growth in that medical device sales unit throughout the rest of this year, which could be another tailwind to this stock and their revenue moving forward here.